Press releases
-
Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
-
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
-
Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
Presentations
In the news
-
Korro Bio Raises $116 Million for RNA Editing Program
-
Korro Bio sings to the tune of $116M for its OPERA RNA editing program
-
RNA-editing startup to double headcount with $116M in new VC
Publications
-
Development of a selection assay for small guide RNAs that drive efficient site-directed RNA editing